- Cangrelor
-
- $0.00 / 1KG
-
2024-08-22
- CAS:163706-06-7
- Min. Order: 10g
- Purity: 99%min
- Supply Ability: 10kg
- CANGRELOR
-
- $20.00 / 1g
-
2021-11-23
- CAS:163706-06-7
- Min. Order: 10g
- Purity: 99.99%
- Supply Ability: 5ton/Month
- Cangrelor
-
- $0.00 / 1g
-
2020-05-17
- CAS:163706-06-7
- Min. Order: 1g
- Purity: 98%
- Supply Ability: 1kg
|
| | CANGRELOR Basic information |
| Product Name: | CANGRELOR | | Synonyms: | CANGRELOR;N-[2-(Methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid anhydride with P,P'-(dichloromethylene)bis[phosphonic acid];AR-C69931 (Cangrelor);Cangrelor (AR-C69931);Kengreal;5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]-N-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine;Cangrelor sodium;[dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid | | CAS: | 163706-06-7 | | MF: | C17H25Cl2F3N5O12P3S2 | | MW: | 776.36 | | EINECS: | 1592732-453-0 | | Product Categories: | API;Pharmaceutical | | Mol File: | 163706-06-7.mol |  |
| | CANGRELOR Chemical Properties |
| Boiling point | 979.0±75.0 °C(Predicted) | | density | 2.08 | | pka | 0.82±0.50(Predicted) |
| | CANGRELOR Usage And Synthesis |
| Uses | Anti-platelet agent. | | Uses | Cangrelor is a P2Y12 inhibitor used as an antiplatelet drug for intravenous application. | | Definition | ChEBI: A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions
N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries. | | Clinical Use | Direct P2Y12 platelet receptor antagonist:
Antiplatelet for patients undergoing a PCI | | Metabolism | Cangrelor is deactivated rapidly in the plasma by
dephosphorylation to form its main metabolite, a
nucleoside. Following a 2 micrograms/kg/min infusion of
[3
H] cangrelor, 58% was found in urine and the remaining
35% was found in faeces, presumably following biliary
excretion. |
| | CANGRELOR Preparation Products And Raw materials |
|